October 3
George Medicines strengthens global commercialization strategy for GMRx2 with exclusive Biolab Farmacêutica licensing agreement in Brazil
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areA clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapy
View ProjectDeveloping disease-modifying mitochondrial therapeutics for neurodegenerative disorders
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectUnlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View ProjectMQ Health is Australia’s first and only fully integrated academic health sciences centre.
ViewThe Baker Heart and Diabetes Institute is an independent, internationally renowned medical research facility, with a history spanning more than 93 years. The Institute's work extends from the laboratory to wide-scale community studies with a focus on diagnosis, prevention and treatment of diabetes and cardiovascular disease.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreGeorge Medicines strengthens global commercialization strategy for GMRx2 with exclusive Biolab Farmacêutica licensing agreement in Brazil
Read moreCUREator+ delivers $15.7 m to local BioMedTech Startups Tackling the Global Dementia Challenge
Read moreNRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
Read moreCUREator BioTech Incubator Grants $1.23M Top-Up Funding to High-Performing Participants
Read more